3,600 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by PDT Partners LLC

PDT Partners LLC purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 3,600 shares of the medical research company’s stock, valued at approximately $853,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Cetera Advisors LLC raised its stake in IQVIA by 28.3% in the 1st quarter. Cetera Advisors LLC now owns 4,464 shares of the medical research company’s stock worth $1,129,000 after acquiring an additional 985 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of IQVIA by 175.2% in the second quarter. GAMMA Investing LLC now owns 809 shares of the medical research company’s stock worth $171,000 after purchasing an additional 515 shares during the last quarter. Massmutual Trust Co. FSB ADV lifted its holdings in shares of IQVIA by 39.2% during the second quarter. Massmutual Trust Co. FSB ADV now owns 994 shares of the medical research company’s stock worth $210,000 after purchasing an additional 280 shares during the period. Versant Capital Management Inc boosted its position in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares during the last quarter. Finally, Mather Group LLC. increased its holdings in IQVIA by 11.6% in the 2nd quarter. Mather Group LLC. now owns 596 shares of the medical research company’s stock worth $126,000 after buying an additional 62 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.5 %

IQV stock opened at $201.79 on Tuesday. The business’s 50-day moving average is $217.89 and its 200 day moving average is $225.88. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The stock has a market cap of $36.62 billion, a price-to-earnings ratio of 26.48, a PEG ratio of 2.07 and a beta of 1.51. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Analysts Set New Price Targets

A number of research firms recently issued reports on IQV. Royal Bank of Canada restated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. The Goldman Sachs Group lowered their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Redburn Atlantic began coverage on IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. Robert W. Baird lowered their price objective on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Finally, Morgan Stanley cut their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.